Semaglutide Research: What the Science Says
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It shares 94% structural homology with native GLP-1 but includes modifications that extend its half-life to approximately one week. The peptide works by enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and acting on central appetite regulation centers. It is FDA-approved in both injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations.
Key Research Highlights
Notable areas of scientific investigation for Semaglutide.
STEP Trial Program for Weight Management
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program demonstrated significant weight reduction with semaglutide 2.4 mg weekly. STEP 1 reported a mean weight loss of approximately 14.9% of body weight at 68 weeks compared to 2.4% with placebo in adults with obesity.
Limitations: Weight regain was observed when the medication was discontinued in the STEP 4 extension study. Gastrointestinal side effects were common, and long-term data beyond two years is still accumulating.
Source: New England Journal of Medicine
SUSTAIN Trials for Type 2 Diabetes
The SUSTAIN trial program evaluated semaglutide in type 2 diabetes across multiple studies. Research demonstrated superior HbA1c reduction compared to placebo and several active comparators including sitagliptin, exenatide extended release, and insulin glargine, with concurrent weight loss benefits.
Limitations: Trial durations were typically 30 to 56 weeks. Pancreatitis risk, though low in trials, remains a labeled concern. Patients with a history of medullary thyroid carcinoma or MEN2 are excluded.
Source: New England Journal of Medicine
SELECT Cardiovascular Outcomes Trial
The SELECT trial evaluated semaglutide 2.4 mg in over 17,500 adults with overweight or obesity and established cardiovascular disease but without diabetes. Results showed a 20% reduction in major adverse cardiovascular events (MACE) over a median follow-up of approximately 40 months.
Limitations: The trial was specific to a population with pre-existing cardiovascular disease. Whether cardiovascular benefits extend to lower-risk populations or are primarily mediated by weight loss versus direct vascular effects is still being studied.
Source: New England Journal of Medicine
Oral Semaglutide Bioavailability
The development of oral semaglutide (Rybelsus) using SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) absorption enhancer technology represented a significant pharmaceutical achievement. The PIONEER trial program demonstrated clinically meaningful glucose and weight effects with the oral formulation.
Limitations: Oral bioavailability is approximately 1%, requiring specific dosing conditions (fasting state, limited water). The oral formulation provides somewhat lower peak concentrations than injection, and its weight loss efficacy is generally less than the higher-dose injectable form.
Source: The Lancet
Effects on Non-Alcoholic Fatty Liver Disease
Research has explored semaglutide in non-alcoholic steatohepatitis (NASH). A Phase 2 trial reported significantly higher rates of NASH resolution without worsening of fibrosis compared to placebo, suggesting hepatoprotective effects potentially related to weight loss and direct metabolic improvements.
Limitations: The Phase 2 NASH trial was relatively small. A fibrosis improvement endpoint was not met. Larger Phase 3 trials are needed to confirm liver-specific benefits and determine if effects persist long-term.
Source: New England Journal of Medicine
What Researchers Are Currently Exploring
Emerging research areas include semaglutide in heart failure with preserved ejection fraction, chronic kidney disease, alcohol use disorder, and neurodegenerative conditions. Higher-dose formulations and combination therapies are also under investigation.
The Bottom Line
Semaglutide has one of the most robust clinical evidence bases of any peptide therapeutic, supported by multiple large, well-designed randomized controlled trials across diabetes, obesity, and cardiovascular disease. The SELECT trial's cardiovascular outcomes data was a landmark finding. FDA approval for multiple indications reflects the strength of this evidence. While generally well-tolerated, gastrointestinal side effects are common, and questions about long-term use, weight regain upon discontinuation, and rare adverse events continue to be studied.
Interested in Semaglutide?
Get matched with a knowledgeable provider who can discuss the research and determine if Semaglutide may be appropriate for your goals.
Get Matched With a Semaglutide ProviderMore About Semaglutide
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Peptide therapies should only be administered by licensed healthcare providers. Always consult with a qualified healthcare professional before starting any new treatment. PeptideLeads is a marketing agency and does not provide medical services.